Now, shares of OCGN stock are down roughly 20% today after negative news from the U.S. Food and Drug Administration (FDA). Specifically, Ocugen announced this morning that the FDA has declined its pediatric Emergency Use Authorization (EUA) application for Covaxin, the company’s vaccine candidate for Covid-19.
Full Answer
Why is ocugen’s stock down?
Mar 08, 2022 · Why Ocugen Stock Is Falling Today By Keith Speights - Mar 8, 2022 at 11:51AM Key Points The FDA slammed the door on an Emergency Use Authorization for its COVID-19 vaccine Covaxin in kids. Ocugen's...
Should you hold ocugen (ocgn) stock?
Mar 04, 2022 · Ocugen (NASDAQ: OCGN) has had a volatile past year, to say the least. For starters, OCGN stock has a 52-week high of $17.65 and a 52-week low of $2.37. That low represents a decrease of 86% from ...
How much of ocugen's stock is owned by institutions?
Feb 23, 2022 · Ocugen Inc. OCGN. shares are trading lower by 19.6% at $3.40 Wednesday morning after the company announced pricing of a $53.5 million public offering of common stock. Ocugen shares were otherwise ...
Is it too late to buy ocugen?
Feb 09, 2022 · From a December 2020 low of about 29 cents, the OCGN stock exploded to a high of $17.65 in recent months for a return of just under 6,000%. It’s all thanks to its coronavirus vaccine, Covaxin....
Is Ocugen a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ocugen stock.
What stocks does MarketBeat like better than Ocugen?
Wall Street analysts have given Ocugen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocugen wasn't one of them.
When is Ocugen's next earnings date?
Ocugen is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.#N#View our earnings forecast for Ocugen.
How were Ocugen's earnings last quarter?
Ocugen, Inc. (NASDAQ:OCGN) released its earnings results on Friday, August, 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.10.#N#View Ocugen's earnings history.
How has Ocugen's stock price been impacted by Coronavirus (COVID-19)?
Ocugen's stock was trading at $0.3612 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OCGN stock has increased by 1,879.5% and is now trading at $7.15.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for OCGN?
5 equities research analysts have issued 12 month price targets for Ocugen's shares. Their forecasts range from $4.50 to $11.00. On average, they anticipate Ocugen's stock price to reach $7.66 in the next year.
Who are some of Ocugen's key competitors?
Some companies that are related to Ocugen include Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Recursion Pharmaceuticals (RXRX), Abcam (ABCM), Sana Biotechnology (SANA), Editas Medicine (EDIT), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Bavarian Nordic A/S (BVNRY), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Relay Therapeutics (RLAY), Translate Bio (TBIO) and BioCryst Pharmaceuticals (BCRX).#N#View all of OCGN's competitors..
Is Ocugen a pre-revenue company?
Ocugen is a pre-revenue company. In other words, it does not have experience in distributing a vaccine at scale. This will definitely be a risk factor and may cause concerns with the FDA.
Who is Tom Taulli?
Tom Taulli ( @ ttaulli) is the author of various books on investing and technology, including Artificial Intelligence Basics, High-Profit IPO Strategies and All About Short Selling. He is also the founder of WebIPO, which was one of the first platforms for public offerings during the 1990s.
/https:%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F91498875%2F0x0.jpg)
Why Ocgn Stock Should Be Avoided
The Company Is Far Behind Its Competition
- Right now, Ocugen has a commercialization agreement with Bharat Biotechthat only covers the United States and Canada. That means OCGN only makes money from the vaccine from any sales in the U.S. and Canada. So a lack of authorizations in both countries is definitely not helping here. Even if authorized, we have to consider that Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) al…
Fortunately, Ocugen Does Have Other Catalysts
- Ocugen still has biologics and therapies in pre-clinical trialsfor: dry age-related macular degeneration, diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration. In addition, the FDA accepted the company’s Investigational New Drug application (IND) to initiate clinical trialsof its gene therapy treatment for retinitis pigmentosa. If those candi…
Bottom Line on Ocgn Stock
- Right now, the company is still burning through cash. There’s no revenue. It’s still not sure if it will receive authorization in the U.S. or Canada. It’s not sure it can carve out a piece of a crowded vaccine market. Plus, its current agreement with Bharat Biotech isn’t so hot. Sure, shares of Ocugen are cheap, but they could get cheaper. With far...